Financial Statements/ESG Information - [Environmental, Social and Governance Information/Report]

CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.

2023 Environmental, Social And Governance & Corporate Social Responsibility Report

Financial Statements/ESG Information - [Annual Report]

2023 Annual Report

Announcements and Notices - [Other - Business Update]

Voluntary Announcement - Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried Obtains Clinical Trial Approval

Voluntary Announcement -
Positive Preliminary Phase I Clinical Results For Protein-Based
Pneumococcal Vaccine

Announcements and Notices - [Date of Board Meeting]

CanSino Biologics (6185 HK)

2023 Environmental, Social And Governance & Corporate Social Responsibility Report

2023 Annual Report

Voluntary Announcement - Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried Obtains Clinical Trial Approval

Voluntary Announcement - Positive Preliminary Phase I Clinical Results For Protein-Based Pneumococcal Vaccine

Notice Of Board Meeting